The Indian cancer genetic research company MedGenome says it has taken $4 million in new funding to further develop and market its genetic sequencing research on cancer victims. MedGenome licenses a bioinformatics database called OncoMD, which containsmore than 1.2 million cancer-related genetic mutations. The funding round was led by Papillon Capitals Kartik Kumaramangalam and Emerge Ventures Mahesh Pratapneni and includes several other individual investors all data science executives. MedGenome is already the leader in the Indian genomics market, says MedGenome CEO Sam Santhosh in a statement today. The new resources from this investment round will enable us to expand our research and make our tools more widely available to clinicians and hospitals developing personalized treatment strategies for cancer patients around the world. Health informatics businesses dont lend themselves to 30-second elevator pitches very well. Heres the short version, as explained to VentureBeatby MedGenome investor Dmitri Mehlhorn. In twins, who have very similar genes, its easy for genetic researchers to understand the small genetic differences that may have led to cancer in one twin but not in the other. Oncologists might be able to recognize that same genetic mutationin other people as a possible warning sign for cancer. But there are … Continue reading →

San Francisco, California (PRWEB) June 05, 2014 The global market for molecular diagnostics is expected to reach USD 8,020.1 million by 2020, according to a new study by Grand View Research, Inc. Growing demand for personalized medicine and theranostics, and the subsequent introduction of advanced cancer diagnostic technologies are expected to be key factors driving market growth over the next six years. Moreover, the growing global base of geriatric population and chronic diseases such as cancer, coupled with disease triggering lifestyle habits such as smoking and excessive alcohol consumption will positively impact market growth. Molecular diagnostic reagent products dominated the overall market, accounting for over 50% of global revenue in 2013. Reagent market revenue is expected to reach USD 4,739.9 million by 2020, growing at a CAGR of 9.9% from 2014 to 2020. High consumption rates of molecular diagnostic reagents and the growing number of research and development initiatives pertaining to the field of molecular diagnostics are two key drivers of this product segment. The point of care end-use market for molecular diagnostics is expected to be the fastest growing product segment, at an estimated CAGR of 13.3% from 2014 to 2020, on account of factors such as the growing … Continue reading →

Stem Cell Therapy Market by Treatment Mode Therapeutic Applications - 2020 [196 Slides Report] Stem Cell Therapy Market report categories the Global market by Therapeutic Applications (CNS, CVS, Musculoskeletal, Wound Healing, GIT, Eye, Immune System), Treatment... By: James Evans … Continue reading →

June 5, 2014 Nathan Hurst, University of Missouri One of the biggest challenges for medical researchers studying the effectiveness of stem cell therapies is that transplants or grafts of cells are often rejected by the hosts. This rejection can render experiments useless, making research into potentially life-saving treatments a long and difficult process. Now, researchers at the University of Missouri have shown that a new line of genetically modified pigs will host transplanted cells without the risk of rejection. The rejection of transplants and grafts by host bodies is a huge hurdle for medical researchers, said R. Michael Roberts, Curators Professor of Animal Science and Biochemistry and a researcher in the Bond Life Sciences Center. By establishing that these pigs will support transplants without the fear of rejection, we can move stem cell therapy research forward at a quicker pace. In a published study, the team of researchers implanted human pluripotent stem cells in a special line of pigs developed by Randall Prather, an MU Curators Professor of reproductive physiology. Prather specifically created the pigs with immune systems that allow the pigs to accept all transplants or grafts without rejection. Once the scientists implanted the cells, the pigs did not … Continue reading →